Adjuvant capecitabine, docetaxel, cyclophosphamide,and epirubicin for early breast cancer: Final analysis of the randomized FinXX trial

Heikki Joensuu, Pirkko Liisa Kellokumpu-Lehtinen, Riikka Huovinen, Arja Jukkola-Vuorinen, Minna Tanner, Riitta Kokko, Johan Ahlgren, Päivi Auvinen, Outi Paija, Leena Helle, Kenneth Villman, Paul Nyandoto, Greger Nilsson, Marjo Pajunen, Raija Asola, Paula Poikonen, Mika Leinonen, Vesa Kataja, Petri Bono, Henrik Lindman

Research output: Contribution to journalArticleScientificpeer-review

80 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Adjuvant capecitabine, docetaxel, cyclophosphamide,and epirubicin for early breast cancer: Final analysis of the randomized FinXX trial'. Together they form a unique fingerprint.

Medicine & Life Sciences